These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 9291802)

  • 1. POMB/ACE chemotherapy for mediastinal germ cell tumours.
    Bower M; Brock C; Holden L; Nelstrop A; Makey AR; Rustin GJ; Newlands ES
    Eur J Cancer; 1997 May; 33(6):838-42. PubMed ID: 9291802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. POMB/ACE chemotherapy for mediastinal germ-cell tumours.
    Droz JP
    Eur J Cancer; 1997 May; 33(6):809-11. PubMed ID: 9291797
    [No Abstract]   [Full Text] [Related]  

  • 3. Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours.
    Fizazi K; Prow DM; Do KA; Wang X; Finn L; Kim J; Daliani D; Papandreou CN; Tu SM; Millikan RE; Pagliaro LC; Logothetis CJ; Amato RJ
    Br J Cancer; 2002 May; 86(10):1555-60. PubMed ID: 12085204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of men with metastatic non-seminomatous germ cell tumours with cyclical POMB/ACE chemotherapy.
    Bower M; Newlands ES; Holden L; Rustin GJ; Begent RH
    Ann Oncol; 1997 May; 8(5):477-83. PubMed ID: 9233528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy for ovarian germ cell tumours.
    Bower M; Fife K; Holden L; Paradinas FJ; Rustin GJ; Newlands ES
    Eur J Cancer; 1996 Apr; 32A(4):593-7. PubMed ID: 8695258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The management and survival of patients with advanced germ-cell tumours: improving outcome in intermediate and poor prognosis patients.
    Bhala N; Coleman JM; Radstone CR; Horsman JM; George J; Hancock BW; Hatton MQ; Coleman RE
    Clin Oncol (R Coll Radiol); 2004 Feb; 16(1):40-7. PubMed ID: 14768754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. POMB/ACE chemotherapy in non-seminomatous germ cell tumours: outcome and importance of dose intensity.
    Husband DJ; Green JA
    Eur J Cancer; 1992; 28(1):86-91. PubMed ID: 1373636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infertility rates following POMB/ACE chemotherapy for male and female germ cell tumours - a retrospective long-term follow-up study.
    Gaffan J; Holden L; Newlands ES; Short D; Fuller S; Begent RH; Rustin GJ; Seckl MJ
    Br J Cancer; 2003 Nov; 89(10):1849-54. PubMed ID: 14612891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platinum-based chemotherapy of primary extragonadal germ cell tumours: the Hellenic Cooperative Oncology Group experience.
    Pectasides D; Aravantinos G; Visvikis A; Bakoyiannis C; Halikia A; Kalofonos C; Kosmidis P; Skarlos D; Fountzilas G
    Oncology; 1999 Jul; 57(1):1-9. PubMed ID: 10394118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The long-term outcome of patients who relapse after chemotherapy for non-seminomatous germ cell tumours.
    Ledermann JA; Holden L; Newlands ES; Begent RH; Rustin GJ; Bagshawe KD; Brampton M
    Br J Urol; 1994 Aug; 74(2):225-30. PubMed ID: 7522874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapy for poor risk germ cell tumours. An independent evaluation of the POMB/ACE regime.
    Cullen MH; Harper PG; Woodroffe CM; Kirkbride P; Clarke J
    Br J Urol; 1988 Nov; 62(5):454-60. PubMed ID: 2463034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary chemotherapy for stage 2 testis cancer.
    Abratt RP; McAdam GL; Pontin AR; Barnes RD; Ball HS
    S Afr J Surg; 1997 Nov; 35(4):203-5; discussion 205-6. PubMed ID: 9540399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surveillance for stage I testicular germ cell tumours: results and cost benefit analysis of management options.
    Francis R; Bower M; Brunström G; Holden L; Newlands ES; Rustin GJ; Seckl MJ
    Eur J Cancer; 2000 Oct; 36(15):1925-32. PubMed ID: 11000572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Combination chemotherapy with POMB/ACE (cisplatin, vincristine, methotrexate, bleomycin, actinomycin D, cyclophosphamide, etoposide) in advanced non-seminomatous testicular tumor].
    Masuda F; Kawahara M; Asano K; Shirakawa H
    Gan To Kagaku Ryoho; 1995 Oct; 22(12):1847-50. PubMed ID: 7574821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcome in patients with germ cell tumours treated with POMB/ACE chemotherapy: comparison of commonly used classification systems of good and poor prognosis.
    Hitchins RN; Newlands ES; Smith DB; Begent RH; Rustin GJ; Bagshawe KD
    Br J Cancer; 1989 Feb; 59(2):236-42. PubMed ID: 2467682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment in germ cell tumours: state of the art.
    Tjan-Heijnen VC; Oosterhof GO; de Wit R; De Mulder PH
    Eur J Surg Oncol; 1997 Apr; 23(2):110-7. PubMed ID: 9158183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term results of two VAB-like regimens (vinblastine + actinomycin-D + bleomycin + cyclophosphamide + cisplatin) in malignant germ cell tumours of the ovary.
    Culine S; Lhomme C; Kattan J; Duvillard P; Michel G; Droz JP
    Eur J Cancer; 1994; 30A(9):1239-44. PubMed ID: 7528029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential resection of residual abdominal and thoracic masses after chemotherapy for metastatic non-seminomatous germ cell tumours.
    Gerl A; Clemm C; Schmeller N; Dienemann H; Weiss M; Kriegmair M; Löhrs U; Wilmanns W
    Br J Cancer; 1994 Nov; 70(5):960-5. PubMed ID: 7524606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving the outcome of salvage treatment for non-seminomatous germ cell tumours (NSGCT).
    de Bono JS; Paul J; Simpson A; Anthoney A; Kirk D; Underwood M; Graham J; Kaye SB
    Br J Cancer; 2000 Aug; 83(4):426-30. PubMed ID: 10945485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in the management of metastatic non-seminomatous germ cell tumours during the cisplatin era: a single-institution experience.
    Gerl A; Clemm C; Schmeller N; Hartenstein R; Lamerz R; Wilmanns W
    Br J Cancer; 1996 Oct; 74(8):1280-5. PubMed ID: 8883418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.